H6D Stock Chart & Stats
€8.60
€0.05(0.58%)
At close: 4:00 PM EDT
€8.60
€0.05(0.58%)
Day’s Range― - ―
52-Week Range€7.35 - €9.65
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€37.39B
Enterprise Value€51.55K
Total Cash (Recent Filing)€821.01M
Total Debt (Recent Filing)€8.20B
Price to Earnings (P/E)19.6
Beta0.30
Next Earnings
Mar 04, 2027EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding4,404,449,700
10 Day Avg. Volume16
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio17.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.55Price Target Upside11.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.48
Revenue Forecast (FY)€13.25B
Bulls Say, Bears Say
Bulls Say
Margin & Cash Flow QualityHaleon’s step-up in gross and net margins alongside FCF conversion near 86% indicates durable earnings quality. Strong cash generation funds organic investment, supports deleveraging and funds the reorganization, giving resilience if top-line growth softens over multiple quarters.
Oral Health Brand StrengthOral Health’s consistent outperformance and Sensodyne’s sustained high single‑digit to double‑digit trend reflect strong brand equity and recurring purchase dynamics. This category supports stable volumes and pricing power, helping sustain margins and provide a platform for reinvestment.
Emerging Markets & E‑commerce GrowthRobust emerging market performance (India, China) and accelerating e‑commerce penetration create structural growth channels. Higher online mix and digital momentum diversify distribution away from mature channels, improving reach and margin profile over the medium term.
Bears Say
Top‑Line & Volume WeaknessPersistently low volume growth (around 1% average) and only 3% organic sales in 2025 signal structural top‑line fragility. Weak volumes limit operating leverage, make profit gains more reliant on cost savings, and complicate sustainable progression toward the company's 4–6% medium‑term target.
Meaningful Absolute Debt LoadDespite improving leverage ratios, an absolute debt stock of ~8.6B constrains strategic flexibility. A sizeable debt burden increases sensitivity to cash‑flow shocks, limits capacity for large M&A or capital returns, and raises refinancing and interest risk if revenue momentum weakens.
U.S. & Pharmacy Channel HeadwindsU.S. market softness and pharmacy destocking create persistent channel risk for a business with significant U.S. exposure. Prolonged retailer inventory adjustments or structural pharmacy changes could depress sell‑through, interrupt shelf presence and delay recovery in a core market over multiple quarters.
Haleon PLC Sponsored ADR News
H6D FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
Haleon PLC Sponsored ADR lowest stock price was €7.35 and its highest was €9.65 in the past 12 months.
What is Haleon PLC Sponsored ADR’s market cap?
Haleon PLC Sponsored ADR’s market cap is €37.39B.
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
Haleon PLC Sponsored ADR’s upcoming earnings report date is Mar 04, 2027 which is in 211 days.
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Haleon PLC Sponsored ADR released its earnings results on Jul 30, 2026. The company reported €0.101 earnings per share for the quarter, missing the consensus estimate of €0.112 by -€0.011.
Is Haleon PLC Sponsored ADR overvalued?
According to Wall Street analysts Haleon PLC Sponsored ADR’s price is currently Undervalued.
Does Haleon PLC Sponsored ADR pay dividends?
Haleon PLC Sponsored ADR does not currently pay dividends.
What is Haleon PLC Sponsored ADR’s EPS estimate?
Haleon PLC Sponsored ADR’s EPS estimate is 0.25.
How many shares outstanding does Haleon PLC Sponsored ADR have?
Haleon PLC Sponsored ADR has 4,404,449,700 shares outstanding.
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Haleon PLC Sponsored ADR reported an EPS of €0.101 in its last earnings report, missing expectations of €0.112. Following the earnings report the stock price went down -1.13%.
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
Currently, no hedge funds are holding shares in DE:H6D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.55 (11.10% Upside)
€9.55 (11.10% Upside)
Blogger Sentiment
Neutral
DE:H6D Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.12%
12-Months-Change
Fundamentals
Return on Equity
1.86%
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Company Description
Haleon PLC Sponsored ADR
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
H6D Company Deck
H6D Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances clear operational and strategic progress (notably strong margin/cost improvements, Oral Health outperformance, emerging markets growth, increased A&P/R&D investment, and a planned $175–$200M cost saving reorganization) against meaningful top-line and volume challenges (soft U.S. market, cold & flu season weakness, category-specific headwinds, and regional retailer/inventory issues). Management presented realistic 2026 guidance (3%–5%) while reiterating confidence in returning to the 4%–6% medium-term ambition as U.S. performance, distribution gains, and productivity benefits materialize.View all DE:H6D earnings summariesH6D Stock 12 Month Forecast
Average Price Target
€9.55
▲(11.10% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―